Wipro partners Transcell for vaccine assessment

Wipro Limited, a leading global information technology, consulting and business process services company, today announced a partnership with Transcell Oncologics to transform vaccine safety assessment using augmented intelligence.

This partnership combines Transcell’s innovative stem cell technology with the advanced augmented intelligence capabilities of Wipro HOLMES to improve the safety of global vaccine immunization programs.

By applying AI to the vaccine development process, our solution is capable of predicting adverse neurovirulent impacts resulting from vaccinations. Currently, vaccine safety assessment often includes testing on animals to measure adverse impacts. Using Wipro HOLMES instead, researchers and biopharmaceutical companies have a new and fully viable solution and alternative.

This partnership will also expand the Wipro HOLMES solutions available to life science companies. The solution applies AI for drug repurposing and Messenger Ribonucleic Acid (mRNA) based platform for biodefense. It enables the testing of new vaccines by applying augmented intelligence to stem cell research and measuring safety and potency. This is the first in a series of next generation solutions that the partnership will offer to determine the safety and efficacy of a wide-range of products from vaccines to prescription medications, cosmetics and more.

Harmeet Chauhan, Global Head – Engineering and R&D, Wipro Limited said, “Our partnership with Transcell Oncologics will bring the best of AI and stem cell technology to researchers, medical professionals and ultimately patients through safe, accelerated vaccination programs.”

Dr. Subhadra Dravida, Founder & CEO, Transcell said, “Deriving new and advanced insights from the use of stem cells in an in vitro setting transforms vaccine safety assessment. This breakthrough process will lead to new medical treatments and accelerate innovation and vaccine availability that is vital to saving lives.”

Share and Enjoy !

0 0

Be the first to comment

Leave a Reply